Podcasts about pancreatic

BUFFALO, NY - June 17, 2025 – A new #research paper was #published in Volume 16 of Oncotarget on June 10, 2025, titled “Exceptional responders to immunotherapy in pancreatic cancer: A multi-institutional case series of a rare occurrence.” The study, led by first author Kavin Sugumar and corresponding author Jordan M. Winter, from University Hospitals Seidman Cancer Center, reports on a rare group of pancreatic cancer (PC) patients who responded remarkably well to immunotherapy, a treatment typically considered ineffective for this cancer type. The analysis, which includes data from 14 patients across multiple U.S. institutions, identifies outcomes that could help refine treatment strategies for one of the most aggressive and deadly forms of cancer. “Between 2020–21, 471 oncologists from 91 major cancer centers in the United States were contacted.” Pancreatic cancer has among the lowest survival rates and few effective therapies. While immunotherapy has transformed the treatment landscape for several other cancers, it generally offers little benefit for pancreatic cancer. However, this study highlights a small but important group of patients who experienced significant and sustained responses to immune-based treatment without chemotherapy. Most had advanced or metastatic disease and had already progressed after standard treatments. Among the 14 patients, 82% had partial tumor shrinkage, and nearly one-third had a notable decrease in tumor markers. The median progression-free survival was 12 months, and most patients were still alive at follow-up, with survival rates of 80% at one year and 70% at two years. These outcomes contrast sharply with standard therapies, which often provide only a few months of benefit for similar patients. Interestingly, while some patients had high microsatellite instability (MSI-high)—a known marker for immunotherapy success—more than half did not, suggesting other biological mechanisms may be involved. This result highlights the need for new biomarkers to be discovered to predict treatment response in future studies. This case series is the largest focused exclusively on exceptional immunotherapy responders in pancreatic cancer. By excluding patients who received chemotherapy, the study isolates the effects of immune-based drugs, including PD-1 inhibitors such as pembrolizumab and nivolumab, CTLA-4 inhibitors like ipilimumab, and agents targeting macrophages. While the sample size is small, the findings challenge the assumption that immunotherapy is ineffective for nearly all pancreatic cancer patients. The study suggests that, under certain biological conditions, this treatment can be remarkably successful. Further research is needed to understand the underlying mechanisms. This work supports the need to reconsider how clinical trials are designed for pancreatic cancer and who is eligible for immunotherapy. Broader criteria and more personalized molecular profiling could help uncover hidden opportunities for treatment in this highly lethal cancer. DOI - https://doi.org/10.18632/oncotarget.28739 Correspondence to - Jordan M. Winter - jordan.winter@UHHospitals.org Video short - https://www.youtube.com/watch?v=VeWTcuVmqgM Sign up for free Altmetric alerts about this article - https://oncotarget.altmetric.com/details/email_updates?id=10.18632%2Foncotarget.28739 Subscribe for free publication alerts from Oncotarget - https://www.oncotarget.com/subscribe/ To learn more about Oncotarget, please visit https://www.oncotarget.com and connect with us: Facebook - https://www.facebook.com/Oncotarget/ X - https://twitter.com/oncotarget Instagram - https://www.instagram.com/oncotargetjrnl/ YouTube - https://www.youtube.com/@OncotargetJournal LinkedIn - https://www.linkedin.com/company/oncotarget Pinterest - https://www.pinterest.com/oncotarget/ Reddit - https://www.reddit.com/user/Oncotarget/ Spotify - https://open.spotify.com/show/0gRwT6BqYWJzxzmjPJwtVh MEDIA@IMPACTJOURNALS.COM

Cancer-fighting implant shows promise in treating melanoma, pancreatic and colorectal tumors. Rice-led study serves as foundation for FDA investigational new drug application and emerging new company to launch from RBL LLC. Veiseh's team at Rice University has created an implant that functions like a “cytokine factory,” delivering IL-12 — a powerful immune-stimulating molecule — directly into the tumor environment. This approach boosts the body's ability to fight cancer while avoiding the severe side effects usually associated with systemic IL-12 therapy.

JCO Editorial Fellow Peter Li and JCO Associate Editor Eileen O'Reilly discuss the ASCO 25 Simultaneous Publication paper "Tumor-Treating Fields with Gemcitabine and Nab-Paclitaxel for Locally Advanced Pancreatic Adenocarcinoma: Randomized, Open-Label, Pivotal, Phase 3 PANOVA-3 Study." Transcript The guest on this podcast episode has no disclosures to declare. Dr. Peter Li: Hello, and welcome to our 2025 ASCO Annual Meeting series, where we cover some of the top JCO papers published simultaneously with their abstract presentation at this year's meeting. I'm your host, Dr. Peter Li, and I'm joined by JCO Associate Editor Dr. Eileen O'Reilly to discuss the Journal of Clinical Oncology article and abstract presentation "Tumor Treating Fields with Gemcitabine and Nab-Paclitaxel for Locally Advanced Pancreatic Adenocarcinoma: Randomized, Open-Label, Pivotal, Phase 3 PANOVA-3 Study." Now, let's start with the relevance of the article. Eileen, can you explain this study to our listeners? Dr. Eileen O'Reilly: Thanks very much, Peter, for the invitation today to discuss this. Yes, so this is a positive phase 3 trial that was conducted in locally advanced, unresectable pancreas cancer. Patients were randomized to receive either gemcitabine and nab-paclitaxel, international standard, with or without tumor-treating fields. And this is a device like a battery pack that you would wear with a goal to wear that approximately 18 hours a day. And the primary endpoint of this study was overall survival, with key secondary endpoints of tumor response, progression-free survival, looking at pain-free survival, and distant progression-free survival. So, the primary endpoint was met with a median overall survival of 16.2 months compared to 14.2 months on the intervention versus control arm, with a hazard ratio of 0.82. And so that met the pre-specified boundary. There was not an increase in progression-free survival, but there was an increase in control of pain on the tumor-treating fields study. So, it was a large, global study, community, academic sites, randomized 570 people, and it supports what I think we've seen in other difficult-to-treat malignancies using tumor-treating fields, that there's a signal of interest. Dr. Peter Li: Can you speak to some of the strengths and weaknesses of this study? Dr. Eileen O'Reilly: So, strengths: it was a large study. It included community sites, it included academic sites. It included ECOG performance status 0, 1, and some patients with 2. The intent was locally advanced. It probably is fair to say that there were some patients who had more advanced disease based on early progression, based on relatively high CA 19-9 for a percentage of people. But likely that was, with random assignment, that would have presumably fallen out between the arms. The inclusion of patients with a lower performance status is nice to see in large phase 3 studies in pancreas cancer. So, they would be some of the strengths. So maybe some of the limitations are the fact that it's an open-label study - so, always some biases inherent in that. Acknowledging that the primary endpoint was overall survival, presumably that wouldn't be directly influenced by that. And there was an imbalance of women on the control arm, and women do fare a little better in this disease, so possibly kind of weighted one of the study arms a little bit. But nonetheless, I think it was a rigorously designed and rigorously conducted phase 3 trial. It's always hard to fully interpret the signal in locally advanced disease because of the fact that some patients go on to surgery, some patients have a treatment switch of cytotoxic therapy, some patients will go on to radiation. And the endpoint here of overall survival, to a degree, eliminates some of that. So, the benchmark, I think, was generally high here. Dr. Peter Li: Gotcha. And then with these findings and this positive study, how do you foresee this research being implemented and how it will impact clinical practice moving forward? Dr. Eileen O'Reilly: I think there'll be an educational need to introduce this approach to the community and to the pancreas cancer world. Again, there's a precedent in glioblastoma and data from other diseases, so there's some familiarity with this. I think people always want to understand how it works and why it works, and that's something that we'll look forward to hearing more about mechanistically, and also seeing how it can be built upon. And there's some intriguing data with the combination of tumor-treating fields and immunotherapy that's being evaluated in the PANOVA-4 study. So, we'll stay tuned to hear how that reads out in due course. But I think overall, it'll be educational and learning, managing the cutaneous impacts or some skin irritation effects from this, and building on this signal in locally advanced disease. Dr. Peter Li: Well, thank you so much, Eileen, for your time and for speaking about the JCO article, "Tumor Treating Fields with Gemcitabine and Nab-Paclitaxel for Locally Advanced Pancreatic Adenocarcinoma: Randomized, Open-Label, Pivotal, Phase 3 PANOVA-3 Study." Join us again for the latest simultaneous publications from the 2025 ASCO Annual Meeting. Please take a moment to rate, review, and subscribe to all ASCO podcast shows at asco.org/podcasts. Until then, enjoy the rest of ASCO 2025. The purpose of this podcast is to educate and to inform. This is not a substitute for professional medical care and is not intended for use in the diagnosis or treatment of individual conditions. Guests on this podcast express their own opinions, experience, and conclusions. Guest statements on the podcast do not express the opinions of ASCO. The mention of any product, service, organization, activity, or therapy should not be construed as an ASCO endorsement.

To have your question featured in a future video, please email: questions@morses.tv Please include at least: Age, Weight and as much history as possible.

In today's episode of Tendrils of Grief, we welcome Julie Barth, a mother of six, trauma survivor, and tireless advocate for women facing life-altering adversity. Julie's story is one of extraordinary resilience—navigating her daughter Tayt's diagnosis with Primordial Dwarfism, her husband Colin's heartbreaking battle with stage-four pancreatic cancer, and the deep wounds of emotional and financial abuse that followed. As the founder and CEO of The Colin James Barth Outreach, Julie has turned her personal grief and trauma into a beacon of hope for women-led households in crisis. Her nonprofit, supported by The Gabby Petito Foundation, provides essential resources and unwavering support to women seeking security, stability, and healing after devastating life events. Through her voice and mission, Julie empowers other women to protect themselves, think resourcefully, and break free from stigma. This conversation is not only a testament to human endurance—but also a call to action for advocacy, healing, and strength. Tune in for an episode that is honest, raw, and deeply moving.      Episode Highlights Turning Trauma Into Purpose Empowering Women Through Grief Navigating Complex Loss and Caregiving Nonprofits Supporting Grieving Families Healing from Emotional Abuse Building Resilience After Loss Parenting Special Needs Children How Grief Shapes Advocacy Work Foundations Inspired by Personal Loss Breaking Stigma Around Women's Self-Protection Julie Barth grief journey Primordial Dwarfism awareness Pancreatic cancer caregiver story Women-led households in crisis Trauma-informed advocacy Nonprofit support for women Colin James Barth Outreach Emotional abuse recovery Resilience after loss Grief and healing podcast Connect with Julie Barth JulieBarthAuthor.net CJBOutreach.org Instagram Facebook TikTok LinkedIn Did you enjoy today's episode?   Please subscribe and leave a review. If you have questions, comments, or possible show topics, email  susan@tendrilsofgrief.com   Don't forget to visit Tendrils Of Grief  website and join for upcoming Webinars, Podcasts Updates and Group Coaching.   Get involve and share your thoughts and experiences in our online community   Tendrils of Grief-Survivor of Loss   To subscribe and review use one links of the links below  Amazon Apple Spotify Audacy Deezer Podcast Addict Pandora Rephonic Tune In  Connect with me Instagram: @Sue_ways Facebook:@ susan.ways Email @susan@tendrilsofgrief.com  Let me hear your thoughts!  

Yi-Chun Chen is taking a close-up look at some of the body's hardest-working cells — the ones often processing an overabundance of modern-day food and nutrients. “From an evolutionary point of view, our cells are not designed to deal with that,” said Dr. Chen, who joined the department of Anatomy, Physiology, and Pharmacology at the University of Saskatchewan last year as an assistant professor. She said our bodies are pushed into churning out large amounts of insulin rapidly after snacks and meals, “which makes the beta cells work extra hard.” Raised in Taiwan and inspired by her grandfather—a retired elementary school science teacher—Chen's fascination with biology first led her to work as a medical laboratory technologist, then to the world of cellular research. Using both rodent and human models, Chen is studying pancreatic beta cells: the way they process peptide hormones like insulin and how their behaviour and function is affected by an excess of nutrients. Using high-resolution imaging, she and her team are examining how both humans and mice synthesize, process, and clear peptide hormones. “There are a lot of things we still don't know about peptide hormones, not just in the pancreas, but in the brain, in the gut,” she said. “Those are fascinating.” Last year, Chen was the recipient of a Canadian Institutes of Health Research Early Career Transition Award. After moving from UBC to Saskatchewan, Dr. Chen said she's thankful to see so much support already from her established and mid-career prairie colleagues. “They can mentor us and guide us, and we also have a group of five or six young scientists,” she said. “I can envision myself working on many, many interesting projects with them.” Her goal today is to identify biomarkers that could predict diabetes far earlier. She hopes to develop biochemical assays that measure proinsulin levels to serve as an early warning system. This could enable interventions months or even years before a traditional diagnosis based on blood glucose levels. “We want to be able to predict the development of, for example, type 1 or type 2 diabetes before they are diagnosed,” said Chen. In the long term, Chen envisions both preventative strategies and regenerative therapies to fight diabetes. Stem cell-derived beta cells may be a future solution, she said. “We are making really good progress in Canada, actually. We have clinical trials. We're putting the stem cell–derived beta cells into patients with type 1 diabetes.” She hopes this will one day reduce the need for constant insulin injections, even helping curb  obesity. “Don't give up,” Chen said. “We are passionate and we want to work on many, many things.” “If you like it, keep going.”

In this episode of Bowel Sounds, hosts Dr. Jenn Lee and Dr. Peter Lu  talk with Dr. Nishant Patel, pediatric gastroenterologist at Orlando Health Arnold Palmer Hospital for Children, about the diagnosis and evaluation of exocrine pancreatic insufficiency (EPI) in children. Learning objectivesRecognize the varied clinical presentations of exocrine pancreatic insufficiency (EPI)Compare the utility, advantages, and limitations of diagnostic tools for EPIApply evidence-based protocols for performing and interpreting ePFTEndoscopic Pancreatic Function Testing (ePFT) in Children: A Position Paper From the NASPGHAN Pancreas CommitteeSupport the showThis episode may be eligible for CME credit! Once you have listened to the episode, click this link to claim your credit. Credit is available to NASPGHAN members (if you are not a member, you should probably sign up). And thank you to the NASPGHAN Professional Education Committee for their review!As always, the discussion, views, and recommendations in this podcast are the sole responsibility of the hosts and guests and are subject to change over time with advances in the field.Check out our merch website!Follow us on Bluesky, Twitter, Facebook and Instagram for all the latest news and upcoming episodes.Click here to support the show.

In this encore episode, we detail the pathophysiology of intestinal methanogen overgrowth (IMO), hydrogen-dominant small intestinal bacterial overgrowth (H₂-SIBO), and hydrogen sulfide-dominant SIBO (H₂S-SIBO), discussing their mechanistic interactions and overlap. We discuss methanogenic archaea, as well hydrogen sulfide- and hydrogen-producing microbes and their contributions to altered gastrointestinal motility, epithelial barrier function, and neuromuscular signaling. We detail host endogenous defense mechanisms, including gastric acid secretion, pancreatic enzymatic activity, bile flow, intestinal motility, and more.Topics:1. Introduction- Overview of intestinal methanogen overgrowth (IMO), hydrogen sulfide-dominant SIBO, and hydrogen-dominant SIBO  - Discussion of overlap  2. Intestinal Methanogen Overgrowth (IMO)- Characterized by an overabundance of methane-producing archaea  - Methane and intestinal transit- Bloating, abdominal discomfort, constipation  - Associated with irritable bowel syndrome with constipation (IBS-C)   3. Overlap Between IMO and SIBO Subtypes- Hydrogen as a substrate for methane and/or hydrogen sulfide production- Shared potential root causes 4. Small Intestinal Bacterial Overgrowth (SIBO) and Protective Mechanisms- The small intestine remains relatively free of bacteria due to protective mechanisms  - Gastric acid secretion - Pancreatic enzymes and bile - Intestinal motility- Structural abnormalities 5. Hydrogen-Dominant SIBO - Increased hydrogen and intestinal transit- Potential symptoms, diarrhea, postprandial bloating  - Different forms of SIBO can coexist  6. Hydrogen Sulfide-Dominant SIBO - H₂S and intestinal motility- H₂S and intestinal epithelial integrity- Symptoms, associations with IBS diarrhea    7. Host Defense Mechanisms Regulating Microbial Balance- Gastric acid secretion, pancreatic enzyme activity, bile flow, intestinal motility, and more 8. Gastric Acid and Its Role in Microbial Regulation- Parietal cells secrete hydrochloric acid (HCl) and intrinsic factor  - Chief cells secrete pepsinogen, conversion into pepsin in acidic conditions  - Gastric acid, digestion and antimicrobial defense   9. Hypochlorhydria - Low gastric acid impairs microbial defense- Reduced acidity disrupts digestion and downstream pancreatic enzyme and bile release   10. Pancreatic Enzymes and Their Role in Microbial Regulation- Pancreatic enzymes, digestion, antimicrobial activity - Enzymes modify chyme to limit fermentable substrates that fuel microbial proliferation   11. Intestinal Motility - Coordinated contractions propel food, microbes, and waste through the GI tract  - The enteric nervous system (ENS) and gut motility- The myenteric plexus controls peristalsis, while the submucosal plexus regulates secretion and absorption   12. Conclusion- Intestinal methanogen overgrowth (IMO), hydrogen-dominant SIBO, and hydrogen sulfide-dominant SIBO - Overlap in symptoms and microbial interactions  - Host defense mechanisms, including gastric acid, pancreatic enzymes, and motility  - Intestinal motility and ENS function in microbial homeostasis  - Hydrogen sulfide as a gasotransmitterGet Chloe's Book Today! "⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠75 Gut-Healing Strategies & Biohacks⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠" Follow Chloe on Instagram ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠@synthesisofwellness⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Visit ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠synthesisofwellness.com⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠

Cancer is among the most common and feared diseases in the modern world. Dr. Selwyn Vickers—president and CEO of Memorial Sloan Kettering Cancer Center—joins host Mark Labberton to discuss how precision oncology, data, and faith are transforming cancer treatment. A distinguished cancer surgeon and pancreatic cancer researcher, Vickers explains how groundbreaking advances in genomics, immunotherapy, and AI are transforming once-lethal diagnoses into survivable and even chronic conditions. Together, they explore not only the cutting-edge science of cancer care but also the spiritual, emotional, and social dimensions that affect every patient and caregiver. Resonating with themes of suffering, hope, and resurrection, this conversation offers clarity, compassion, and courage for all who are affected by cancer—from those newly diagnosed, to medical professionals, to grieving families and curious listeners. Episode Highlights “We're getting to a point where we will, in the next five to seven years, have a much better chance to cure people—and to make pancreatic cancer a chronic illness.” “We are in what's somewhat coined the golden age of cancer research.” “Cancer is a disease that creates an existential threat in ways no other illness does.” “If a tumour forms, it means your body's immune system has made a social contract with the cancer.” “We changed the diagnosis in 10–12 percent of the patients who come to us—sometimes from cancer to no cancer.” “Cancer care is a team sport. And our patients often inspire us more than we help them.” Helpful Links & Resources Memorial Sloan Kettering Cancer Center BioNTech – creators of mRNA vaccines for COVID and cancer CAR T-Cell Therapy Overview (Cancer.gov) Tim Keller on cancer and hope Emma Thompson's Wit (HBO) BRCA1 and BRCA2 Genes and Cancer Risk MSK-IMPACT: Next-Gen Tumor Profiling About Selwyn Vickers Selwyn M. Vickers, MD, FACS, is the president and CEO of Memorial Sloan Kettering Cancer Center (MSK) and the incumbent of the Douglas A. Warner III Chair. He assumed the role on September 19, 2022. Vickers is an internationally recognized pancreatic cancer surgeon, pancreatic cancer researcher, and pioneer in health disparities research. He is a member of the National Academy of Medicine and the Johns Hopkins Society of Scholars. He has served on the Johns Hopkins School of Medicine Board of Trustees and the Johns Hopkins University Board of Trustees. Additionally, he has served as president of the Society for Surgery of the Alimentary Tract and the Southern Surgical Association. Vickers is the immediate past president of the American Surgical Association. He also continues to see patients. In 1994, he joined the faculty of the University of Alabama at Birmingham (UAB) as an assistant professor in the Department of Surgery, where he was later appointed to professor and the John H. Blue Chair of General Surgery. In 2006, Vickers left UAB to become the Jay Phillips Professor and Chair of the Department of Surgery at the University of Minnesota Medical School. Born in Demopolis, Alabama, Vickers grew up in Tuscaloosa and Huntsville. He earned baccalaureate and medical degrees and completed his surgical training (including a chief residency and surgical oncology fellowship) at the Johns Hopkins University. Vickers completed two postgraduate research fellowships with the National Institutes of Health and international surgical training at John Radcliffe Hospital of Oxford University, England. Vickers and his wife, Janice, who is also from Alabama, have been married since 1988. They have four children. Show Notes The ongoing threat and fear of cancer How Selwyn Vickers got into medicine Pancreatic cancer: Vickers's expertise “We are in what's somewhat coined the golden age of cancer research.” Sequencing the human genome “Is there a drug that might target the mutation that ended up creating your cancer?” Cancer as both a medical and existential diagnosis The revolution of precision oncology through human genome sequencing ”It takes a billion cells to have a one centimetre tumor.” Immunotherapy: checkpoint inhibition, CAR T-cell therapy, and vaccines Cellular therapy:   ”Taking a set of their normal cells and re-engineering them to actually go back and target and attack their tumors. … We've seen patients who had initially a 30 percent chance of survival converted to an 80 percent chance of survival.” “We know in many tumours there's something called minimal residual disease.” “Immunizing yourself against cancer is a significant future opportunity.” Managing the power of data with AI and computational oncology Cancer-care data explosion: the role of computational oncologists Cancer vaccines: breakthrough mRNA treatment for pancreatic cancer ”Didn't ultimately win. We had to suffer through her losing her life, but was so appreciative that she got much more than the six months she was promised.” Tumour misdiagnoses and the importance of specialized expertise Pancreatic cancer challenges: immune cloaking and late-stage detection In the past, one in four would die from the operation for removing pancreatic cancer Long-term survival Future of cancer detection: AI-based medical record analysis and blood biopsies More accurate blood tests to confirm conditions Using AI to select those who are high-risk for cancer Pastor Tim Keller died of pancreatic cancer. In the past, “your doctor … helped you learn how to die.” ”[God's] given man the privilege to discover those things that have been hidden. And over time we've gradually uncovered huge opportunities to impact people's lives.” The state of breast cancer research and treatment “If you get the diagnosis of breast cancer, you have a 90 percent chance to survive and beat it over a five-year period of time.” ”In general, we're in a great state of understanding how to treat breast cancer, how to detect it early, and then have selective and targeted mechanisms to prevent it from coming back.” Prostate cancer research and treatment Theranostics: using a specific antibody to target cancer cells specifically Pediatric cancer:  ”We actually treat more children for cancer than any hospital in America now, but in general, the survival for pediatric cancers is greater than 80 percent.” Emotional, psychological, and spiritual toll of cancer: importance of psycho-oncology How Sloan Kettering developed psycho-oncology to help cancer patients with mental and spiritual health Personal story: how a cafeteria worker empowers patients through food choices “We give back to them the right to choose what they get to have on their tray.” Cancer treatment is a team sport. Wit (film, Broadway play)—actress Emma Thompson plays a cancer patient studying the work of John Donne on death Socioeconomic and racial disparities in cancer care outcomes The healing role of community, support teams, and compassionate listening The importance of listening to cancer patients who are preparing to die The spiritual courage of patients and the transformative power of faith “Our patients often help us. We see the grace with which they often handle that journey.” The inspiration behind becoming a doctor: family legacy and human impact Terminal care: the sacred responsibility of walking with patients to the end Cancer research and treatment as a Christian vocation and expression of humanity Production Credits

    Nayana Ferguson shares her experience facing both pancreatic cancer and breast cancer and rewriting her Next Chapter. After earning a successful corporate career and recovering from her health challenges, Nayana and her husband, Don, followed a dream. They launched Anteel Tequila in 2018 and have been racking up awards ever since. Nayana joins a small but growing of fearless black women launching successful spirits brands.Fearless Fabulous You is broadcast live Wednesdays at 12 Noon ET on W4WN Radio - Women 4 Women Network (www.w4wn.com) part of Talk 4 Radio (www.talk4radio.com) on the Talk 4 Media Network (www.talk4media.com).Fearless Fabulous You Podcast is also available on Talk 4 Media (www.talk4media.com), Talk 4 Podcasting (www.talk4podcasting.com), iHeartRadio, Amazon Music, Pandora, Spotify, Audible, and over 100 other podcast outlets.

CME credits: 0.25 Valid until: 16-04-2026 Claim your CME credit at https://reachmd.com/programs/cme/second-line-chemotherapy-options-in-metastatic-pdac/33136/ Pancreatic ductal adenocarcinoma, also known as PDAC, is a lethal disease that is usually diagnosed at an advanced stage with an extremely poor prognosis. Advancements in treatment regimens have improved survival rates, but early diagnosis is crucial for improving outcomes, and awareness of risk factors is vital for early diagnosis. Cytotoxic chemotherapy is the cornerstone of treatment for advanced or metastatic cases, although molecularly targeted therapies and immunotherapies may benefit select patients. Treatment selection depends on several factors, including patients' performance status and comorbidities, which should be considered alongside the efficacy and safety profiles of the different chemotherapy regimens. This two-part programme provides an overview of the different first- and second-line chemotherapy options. Complete both modules, answer pre- and post-test questions and start earning CME credits. This programme is also featured on the COR2ED website, here: Chemotherapy Strategies for Metastatic Pancreatic Ductal Adenocarcinoma

CME credits: 0.25 Valid until: 16-04-2026 Claim your CME credit at https://reachmd.com/programs/cme/first-line-chemotherapy-options-in-metastatic-pdac/33135/ Pancreatic ductal adenocarcinoma, also known as PDAC, is a lethal disease that is usually diagnosed at an advanced stage with an extremely poor prognosis. Advancements in treatment regimens have improved survival rates, but early diagnosis is crucial for improving outcomes, and awareness of risk factors is vital for early diagnosis. Cytotoxic chemotherapy is the cornerstone of treatment for advanced or metastatic cases, although molecularly targeted therapies and immunotherapies may benefit select patients. Treatment selection depends on several factors, including patients' performance status and comorbidities, which should be considered alongside the efficacy and safety profiles of the different chemotherapy regimens. This two-part programme provides an overview of the different first- and second-line chemotherapy options. Complete both modules, answer pre- and post-test questions and start earning CME credits. This programme is also featured on the COR2ED website, here: Chemotherapy Strategies for Metastatic Pancreatic Ductal Adenocarcinoma

Pancreatic cancer is one of the deadliest types of cancer. It's known as the “silent killer” because, by the time you know you have it, it's often too late. Pay attention to these 7 early warning signs of pancreatic cancer.1. Sudden unexpected weight lossA problem with the pancreas can affect digestion and appetite, which can cause you to lose weight unexpectedly. 2. Abdominal painThis is typically dull, persistent pain that can radiate to the left shoulder. Sometimes, it shows up as radiating pain in the belly button that extends into the spine and often feels worse after eating. 3. Jaundice This is characterized by yellowing of the whites of the eyes and rust-colored urine caused by bile backing up into the blood. TUDCA can be a good remedy for this! Take two on an empty stomach twice a day to open the bile ducts. 4. Chronic diarrhea Most pancreatic cancer affects the part of the pancreas that is responsible for digestive enzymes, which can often lead to chronic diarrhea. 5. Diabetes A tumor in the pancreas can disrupt the cells that produce insulin, contributing to diabetes. 6. Feeling full quickly Pancreatic cancer can cause you to feel full and bloated even If you've hardly had anything to eat.7. Persistent fatigue This can be described as overwhelming, chronic fatigue that doesn't improve with more sleep.Don't consume sugar if you have pancreatic cancer!Risk factors for pancreatic cancer include the following:•Smoking tobacco •Type 2 diabetes •Obesity •Alcohol consumption•Genetic factors•Vitamin D deficiency Vitamin D may help shrink cancer and enhance the immune system's ability to fight cancer.To help prevent pancreatic cancer:•Ensure you're getting enough sleep •Reduce stress•Exercise •Practice intermittent fasting Incorporating anti-cancer foods such as cruciferous vegetables, green tea, garlic, and berberine may help. Dr. Eric Berg DC Bio:Dr. Berg, age 59, is a chiropractor who specializes in Healthy Ketosis & Intermittent Fasting. He is the author of the best-selling book The Healthy Keto Plan, and is the Director of Dr. Berg Nutritionals. He no longer practices, but focuses on health education through social media.

DITCH YOUR DOCTOR! https://www.livelongerformula.com/wam Get a natural health practitioner and work with Christian Yordanov! Mention WAM and get a FREE masterclass! HELP SUPPORT US AS WE DOCUMENT HISTORY HERE: https://gogetfunding.com/help-wam-cover-history/ GET NON-MRNA FREEZE DRIED MEAT HERE: https://wambeef.com/ Use code WAMBEEF to save 20%! GET HEIRLOOM SEEDS & NON GMO SURVIVAL FOOD HERE: https://heavensharvest.com/ USE Code WAM to save 5% plus free shipping! GET YOUR APRICOT SEEDS at the life-saving Richardson Nutritional Center HERE: https://rncstore.com/r?id=bg8qc1 Josh Sigurdson reports on the news of Big Pharma biotech billionaire and inventor of cancer drug Abraxane, Dr. Patrick Soon-Shiong declaring that the Covid "vaccine" has caused a massive uptick in cancer. Dr. Soon-Shiong is also the owner of the LA Times which has pushed pro covid vaccine propaganda on the masses for years including just recently. This is a big admission but obviously years late. The doctor pointed out that he's seeing metastatic pancreatic cancer in children as young as 13 which is extremely unusual. Pancreatic cancer usually only affects people 70 and older. It was a shock in 1991 when Michael Landon, actor and legendary TV producer was diagnosed with pancreatic cancer at 54 years old and died within 12 weeks. That was considered young. Now, here we are 3 decades later and it's being normalized to see young teens die from the horrible ailment. Moderna had previously confirmed last year that their mRNA "vaccines" cause cancer and in an exposed coverup, Pfizer had acknowledged behind closed doors that their injections did the same. Meanwhile, the latest normalization of disease related fear continues as Bird Flu propaganda is painted all over the media with claims that bobcats are spreading it as well as cat food. This is clearly an intro to the agenda to target the food supply and inject store bought meats with modRNA while simultaneously restricting food to rations. This is something the WEF has proclaimed they want to do so don't be surprised if we shift in that direction fast. In this video, we break down the latest propagandist claims and the real solutions before our eyes. Stay tuned for more from WAM! Get local, healthy, pasture raised meat delivered to your door here: https://wildpastures.com/promos/save-20-for-life/bonus15?oid=6&affid=321 USE THE LINK & get 20% off for life and $15 off your first box! SIGN UP FOR HOMESTEADING COURSES NOW: https://freedomfarmers.com/link/17150/ Get Prepared & Start The Move Towards Real Independence With Curtis Stone's Courses! GET YOUR WAV WATCH HERE: https://buy.wavwatch.com/WAM Use Code WAM to save $100 and purchase amazing healing frequency technology! GET ORGANIC CHAGA MUSHROOMS HERE: https://alaskachaga.com/wam Use code WAM to save money! See shop for a wide range of products! GET AMAZING MEAT STICKS HERE: https://4db671-1e.myshopify.com/discount/WAM?rfsn=8425577.918561&utm_source=refersion&utm_medium=affiliate&utm_campaign=8425577.918561 USE CODE WAM TO SAVE MONEY! GET YOUR FREEDOM KELLY KETTLE KIT HERE: https://patriotprepared.com/shop/freedom-kettle/ Use Code WAM and enjoy many solutions for the outdoors in the face of the impending reset! BUY GOLD HERE: https://firstnationalbullion.com/schedule-consult/ PayPal: ancientwonderstelevision@gmail.com FIND OUR CoinTree page here: https://cointr.ee/joshsigurdson JOIN US on SubscribeStar here: https://www.subscribestar.com/world-alternative-media For subscriber only content! Pledge here! Just a dollar a month can help us alive! https://www.patreon.com/user?u=2652072&ty=h&u=2652072 BITCOIN ADDRESS: 18d1WEnYYhBRgZVbeyLr6UfiJhrQygcgNU World Alternative Media 2025

Dr Charlie Andrews talks to Dr John Leeds. John Leeds is a Consultant Pancreaticobiliary Physician and Endoscopist based at the Freeman Hospital in Newcastle and an Honorary Clinical Senior Lecturer based in the Population Health Sciences Institute at Newcastle University. He is involved in research in pancreaticobiliary disorders including benign and malignant conditions as well as outcomes from therapeutic/advanced endoscopy.John is a member of the British Society of Gastroenterology and Pancreatic Society of Great Britain and Ireland. He serves on the endoscopy and Pancreas committees for BSG and is the website lead for PSGBI.He is also a founder member of the BSG Pancreas Clinical Research Group which is coordinating research for the society.Key Learnings from this episode:Challenges in Early Detection of Pancreatic Cancer • Pancreatic cancer is often diagnosed at an advanced stage due to the deep location of the pancreas and the lack of early symptoms. • Tumors in the body and tail of the pancreas can grow significantly before causing symptoms, often invading major arteries or veins, making them inoperable. • Tumors in the head of the pancreas may present earlier due to bile duct obstruction, leading to jaundice, but even these are often detected late. Early Symptoms and Red Flags • Early symptoms are vague or absent, making early diagnosis difficult. • Possible early indicators include: • Weight loss (often a sign of advanced disease). • New-onset diabetes, particularly in individuals with a normal BMI or without typical risk factors for type 2 diabetes. • Jaundice, which is a significant red flag and often indicates a serious underlying condition. • Classic signs like painless jaundice and Courvoisier's sign (palpable gallbladder) are important but not always present. Limitations of Current Screening Methods • There is no reliable biomarker or screening test for pancreatic cancer: • CA19-9 is not suitable as a screening tool due to its lack of specificity (elevated in other conditions). • Imaging techniques like CT scans or MRIs are used but have limitations, including incidental findings that may lead to unnecessary anxiety (“scanxiety”) and over-investigation. • Screening is currently limited to high-risk groups, such as those with familial pancreatic cancer syndromes or hereditary pancreatitis. High-Risk Groups for Screening • Familial pancreatic cancer accounts for less than 10% of cases. Criteria for screening include: • Multiple family members with pancreatic cancer, especially diagnosed under age 50–60. • Genetic syndromes like BRCA mutations, familial adenomatous polyposis (FAP), and Peutz-Jeghers syndrome. • Hereditary pancreatitis patients have an increased risk but are harder to screen due to pre-existing pancreatic abnormalities. Emerging Research and Future Directions • Studies are exploring potential biomarkers, such as microbiome signatures in the pancreas, which might help identify high-risk individuals in the future. • Trials like the EuroPAC study focus on surveillance protocols for high-risk individuals using imaging techniques like MRI or endoscopic ultrasound. • Research into new-onset diabetes as a potential marker for pancreatic cancer is ongoing but currently has a low yield due to the high prevalence of type 2 diabetes unrelated to malignancy. Considerations for Screening and Surveillance • Screening should be carefully targeted to avoid over-diagnosis and unnecessary investigations. • The psychological impact of screening (e.g., anxiety from incidental findings) must be considered. • Smoking cessation is emphasized as smoking is a significant risk factor for pancreatic cancer. Advances in Treatment Approaches • PET-CT scans are increasingly used to detect systemic disease that might not be evident on standard CT scans. • Neoadjuvant treatments (therapy before surgery) are being... Chapters (00:00:00) - Ingest(00:00:53) - Pancreatic Cancer(00:04:03) - New diabetes and pancreatic cancer(00:08:01) - Pancreatic Cancer: Screening(00:15:42) - Determining breast cancer early is hard(00:16:03) - Pulmonary neuroendocrine tumors of the pancreas(00:22:26) - Pancreatic cancer 20, Management(00:29:00) - Pancreatic cancer, management principles(00:33:48) - Primary Care Take Home: Pancreas, pain(00:40:29) - Primary Care: Pancreas Cancer Episode 2

Dr Charlie Andrews talks to Dr John Leeds. John Leeds is a Consultant Pancreaticobiliary Physician and Endoscopist based at the Freeman Hospital in Newcastle and an Honorary Clinical Senior Lecturer based in the Population Health Sciences Institute at Newcastle University. He is involved in research in pancreaticobiliary disorders including benign and malignant conditions as well as outcomes from therapeutic/advanced endoscopy.John is a member of the British Society of Gastroenterology and Pancreatic Society of Great Britain and Ireland. He serves on the endoscopy and Pancreas committees for BSG and is the website lead for PSGBI.He is also a founder member of the BSG Pancreas Clinical Research Group which is coordinating research for the society. Chapters (00:00:01) - Ingest: pancreatic lesions(00:01:09) - Pancreas(00:05:39) - Chronic Pancreas disease, early signs and symptoms(00:11:54) - Pulmonary pancreatitis, diagnosis and management(00:17:52) - Diarrhea, weight loss(00:18:29) - Pancreatic disease, ultrasound and the best treatment(00:23:49) - Pancreatitis, chronic pancreatitis in primary care(00:26:19) - Pancreatitis 20, Surgery or drainage?(00:32:24) - Pancreatic Exocrine Insufficiency(00:38:05) - Pulmonary dysrhythmias, management tips(00:43:46) - PPI for cystic fibrosis patients 8,(00:46:16) - Pancreatic insufficiency 20, Detection and treatment(00:49:57) - Pancreatic cysts(00:55:32) - Choosing the right cyst for surgery(00:57:20) - autoimmune pancreatitis, presentation and treatment(01:03:34) - Pancreatic cancer: diagnosis and treatment(01:06:14) - Pancreatitis, part 1, unboxing

Cancer is not a singular disease but a category of hundreds, even thousands, of rare diseases with different molecular signatures and genetic roots. Cancer scientists are looking for a thousand perfect keys to pick a thousand stubborn locks. Today's episode is about the hardest lock of them all: pancreatic cancer. Cancer's power lives in its camouflage. The immune system is often compared to a military search and destroy operation, with our T cells serving as the expert snipers, hunting down antigens and taking them out. But cancer kills so many of us because it looks so much like us. Pancreatic cancer is so deadly in part because it's expert at hiding itself from the immune system. Now, here's the good news. This might be the brightest moment for progress in  pancreatic cancer research in decades—and possibly ever. In the past few years, scientists have developed new drugs that target the key gene mutation responsible for out of control cell growth. Recently, a team of scientists at Oregon Health and Science University claimed to have developed a blood test that is 85 percent accurate at early-stage detection of pancreatic cancer, which is absolutely critical given how advanced the cancer is by the time it's typically caught. And last month, a research center at Memorial Sloan Kettering published a truly extraordinary paper. Using mRNA technology similar to the COVID vaccines, a team of scientists designed a personalized therapy to buff up the immune systems of people with pancreatic cancer. Patients who responded to the treatment saw results that boggle the mind: 75 percent were cancer-free three years after their initial treatment. Not just alive, which would be its own minor miracle. But cancer-free. The mRNA vaccine, administered within a regimen of standard drugs, stood up to the deadliest cancer of them all and won. Today's guest is the head of that research center, the surgical oncologist Vinod Balachandran. The concept of a personalized cancer vaccine is still unproven at scale. But if it works, the potential is enormous. But again: Cancer does not exist, as a singular disease. Cancer is a category of rare diseases, many of which are exquisitely specific to the molecular mosaic of the patient. Cancers are personal. Perhaps in a few years, our cures for cancers will be equally personalized. If you have questions, observations, or ideas for future episodes, email us at PlainEnglish@Spotify.com. Host: Derek Thompson Guest: Vinod Balachandran Producer: Devon Baroldi Links:  Cancer Vaccine paper: https://www.nature.com/articles/s41586-024-08508-4 P.S. Derek wrote a new book! It's called 'Abundance,' and it's about an optimistic vision for politics, science, and technology that gets America building again. Buy it here: https://www.simonandschuster.com/books/Abundance/Ezra-Klein/9781668023488 Plus: If you live in Seattle, Atlanta, or the Raleigh-Durham-Chapel Hill area, Derek is coming your way in March! See him live at book events in your city. Tickets here: The Abundance Book Tour Learn more about your ad choices. Visit podcastchoices.com/adchoices

In this episode, we detail the pathophysiology of intestinal methanogen overgrowth (IMO), hydrogen-dominant small intestinal bacterial overgrowth (H₂-SIBO), and hydrogen sulfide-dominant SIBO (H₂S-SIBO), discussing their mechanistic interactions and overlap. We discuss methanogenic archaea, as well hydrogen sulfide- and hydrogen-producing microbes and their contributions to altered gastrointestinal motility, epithelial barrier function, and neuromuscular signaling. We detail host endogenous defense mechanisms, including gastric acid secretion, pancreatic enzymatic activity, bile flow, intestinal motility, and more.Topics:1. Introduction- Overview of intestinal methanogen overgrowth (IMO), hydrogen sulfide-dominant SIBO, and hydrogen-dominant SIBO  - Discussion of overlap  2. Intestinal Methanogen Overgrowth (IMO)- Characterized by an overabundance of methane-producing archaea  - Methane and intestinal transit- Bloating, abdominal discomfort, constipation  - Associated with irritable bowel syndrome with constipation (IBS-C)   3. Overlap Between IMO and SIBO Subtypes- Hydrogen as a substrate for methane and/or hydrogen sulfide production- Shared potential root causes 4. Small Intestinal Bacterial Overgrowth (SIBO) and Protective Mechanisms- The small intestine remains relatively free of bacteria due to protective mechanisms  - Gastric acid secretion - Pancreatic enzymes and bile - Intestinal motility- Structural abnormalities 5. Hydrogen-Dominant SIBO - Increased hydrogen and intestinal transit- Potential symptoms, diarrhea, postprandial bloating  - Different forms of SIBO can coexist  6. Hydrogen Sulfide-Dominant SIBO - H₂S and intestinal motility- H₂S and intestinal epithelial integrity- Symptoms, associations with IBS diarrhea    7. Host Defense Mechanisms Regulating Microbial Balance- Gastric acid secretion, pancreatic enzyme activity, bile flow, intestinal motility, and more 8. Gastric Acid and Its Role in Microbial Regulation- Parietal cells secrete hydrochloric acid (HCl) and intrinsic factor  - Chief cells secrete pepsinogen, conversion into pepsin in acidic conditions  - Gastric acid, digestion and antimicrobial defense   9. Hypochlorhydria - Low gastric acid impairs microbial defense- Reduced acidity disrupts digestion and downstream pancreatic enzyme and bile release   10. Pancreatic Enzymes and Their Role in Microbial Regulation- Pancreatic enzymes, digestion, antimicrobial activity - Enzymes modify chyme to limit fermentable substrates that fuel microbial proliferation   11. Intestinal Motility - Coordinated contractions propel food, microbes, and waste through the GI tract  - The enteric nervous system (ENS) and gut motility- The myenteric plexus controls peristalsis, while the submucosal plexus regulates secretion and absorption   12. Conclusion- Intestinal methanogen overgrowth (IMO), hydrogen-dominant SIBO, and hydrogen sulfide-dominant SIBO - Overlap in symptoms and microbial interactions  - Host defense mechanisms, including gastric acid, pancreatic enzymes, and motility  - Intestinal motility and ENS function in microbial homeostasis  - Hydrogen sulfide as a gasotransmitterThank you to our episode sponsors:1. Shop ⁠⁠⁠⁠⁠Fresh Press Farms⁠⁠⁠'⁠⁠⁠⁠Peach Cider Vinegar⁠⁠ at Sprouts locations nationwide, and check out their full collection ⁠⁠⁠⁠⁠here⁠⁠⁠⁠⁠. 2. Shop ⁠CYLN's⁠ full skincare line ⁠here⁠.Get Chloe's Book Today! "⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠75 Gut-Healing Strategies & Biohacks⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠" Follow Chloe on Instagram ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠@synthesisofwellness⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Visit ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠synthesisofwellness.com⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠

Alicia is a passionate life enthusiast whose perspective was profoundly transformed by her experience with Stage 3 Pancreatic cancer in April 2021. There were ups and downs every step of the way, there were many teachings and challenges. She had 7+ hour robotic Whipple surgery with a very challenging recovery followed by chemotherapy. During her treatment and recovery Alicia adopted all 10 of the Radical Remission Healing Factors. She believes that if cancer hadn't knocked on her door, she would have never changed. She never would have felt so much happiness by watching a sunset or a sunrise, sharing experiences in the physical with the people she loves, or the simple pleasures in life like a great cup of warm tea in her hands on a chilly morning. Today, Alicia cherishes her time with Picasso, her beloved horse, and enjoys invigorating walks and heartwarming conversations with her dog, Tequila-Pepper. However, her greatest joy comes from sharing every day with her husband, Per, as they navigate life's journey together as co-conspirators.  To connect with Alicia you can email her - avila.alicia@gmail.com Resources: www.cognomovement.com  https://pancreasfoundation.org/patient-resources/camp-hope/ ________________ To learn more about the 10 Radical Remission Healing Factors, connect with a certified RR coach or join a virtual or in-person workshop visit www.radicalremission.com. To watch Episode 1 of the Radical Remission Docuseries for free, visit our YouTube channel here.  To purchase the full 10-episode Radical Remission Docuseries visit Hay House Online Learning. To learn more about Radical Remission health coaching with Liz or Karla, Click Here Follow us on Social Media: Facebook  Instagram YouTube  

This ASPEN podcast series is based on the Nutrition in Clinical Practice Supplement titled ‘Fat Malabsorption in Disease States' published in April 2024. This episode features David Evans, MD, focusing on exocrine pancreatic insufficiency related to pancreatectomy and other gastrointestinal surgery. This podcast series provides an in-depth look at the latest understanding of fat malabsorption in various disease states and was developed to educate clinicians on the current evidence in the management of this condition. This podcast is supported by Alcresta. Business Corporate by Alex Menco | alexmenco.net Music promoted by www.free-stock-music.com Creative Commons Attribution 3.0 Unported License creativecommons.org/licenses/by/3.0/deed.en_US March 2025

This ASPEN podcast series is based on the Nutrition in Clinical Practice Supplement titled ‘Fat Malabsorption in Disease States' published in April 2024. This episode features Amy Berry, MS, RD, focusing on exocrine pancreatic insufficiency and management with pancreatic exocrine replacement therapy. This podcast series provides an in-depth look at the latest understanding of fat malabsorption in various disease states and was developed to educate clinicians on the current evidence in the management of this condition. This podcast is supported by Alcresta. Business Corporate by Alex Menco | alexmenco.net Music promoted by www.free-stock-music.com Creative Commons Attribution 3.0 Unported License creativecommons.org/licenses/by/3.0/deed.en_US March 2025

Sweden's fastest growing private biotech, Anocca, is making plans for clinical trials in pancreatic cancer, with the TCR-T cell therapy trials called VIDAR-1.The CEO, Reagan Jarvis, when a researcher, pitched the company idea to a leading Swedish industrialist, who became co-founder, and provided the initial financing. The company has raised more than €100m to date.On the podcast this week, we have a conversation with Jarvis about TCR-T cell therapies, creating off-the-shelf products and partnerships with EmendoBio and Shinobi Therapeutics.00:43-02:10: About Anocca 02:10-04:16: About TCR-T cell therapies and their use in treatments04:16-06:02: Anocca's approach to T-cell biology, cutting-edge biotechnologies and integrated software06:02-07:58: A different approach to other cell and gene therapy companies07:58-09:16: Facing challenges09:16-10:48: Addressing conditions and diseases10:48-11:54: Pancreatic cancer11:54-13:40: What represents success for Anocca?13:40-14:09: What is VIDAR-1?14:09-16:08: Partnerships16:08-18:05: Scaling up and addressing costs18:05-20:07: How is TCR-T therapy evolving?20:07-23:11: The impact of artificial intelligence23:11-25:16: Anocca timeline25:16-25:57: Closing comments  `Interested in being a sponsor of an episode of our podcast? Discover how you can get involved here! Stay updated by subscribing to our newsletter

Pancreatic cancer is notoriously difficult to treat, and about 90% of diagnosed patients die from the disease. A team at Memorial Sloan Kettering has been working to improve those outcomes by developing a new mRNA vaccine for pancreatic cancer.A few years ago, the team embarked on a small trial to test the vaccine's safety. Sixteen patients with pancreatic cancer received it, and even though it was a small study, the results were promising: Half the participants had an immune response, and in those patients the cancer hadn't relapsed after 18 months.This week, the team released a new study in Nature following those same patients, and found six out of eight who responded to the vaccine in the first study did not have their cancer return more than three years later.Joining host Flora Lichtman to talk about these results, and what they could mean for the future of cancer treatment, is study author and surgeon Dr. Vinod Balachandran, director of The Olayan Center for Cancer Vaccines at Memorial Sloan Kettering, based in New York City.Transcripts for each segment will be available after the show airs on sciencefriday.com.  Subscribe to this podcast. Plus, to stay updated on all things science, sign up for Science Friday's newsletters.

Pancreatic islet biology and Diabetes (link) Free Juicebox Community (non Facebook) JUICE CRUISE 2025 Blue Circle Health Eversense CGM Learn about the Medtronic Champions Try delicious AG1 - Drink AG1.com/Juicebox I Have Vision Use code JUICEBOX to save 40% at Cozy Earth  CONTOUR NextGen smart meter and CONTOUR DIABETES app Learn about the Dexcom G6 and G7 CGM Go tubeless with Omnipod 5 or Omnipod DASH * Get your supplies from US MED  or call 888-721-1514 Learn about Touched By Type 1 Take the T1DExchange survey *The Pod has an IP28 rating for up to 25 feet for 60 minutes. The Omnipod 5 Controller is not waterproof.  How to listen, disclaimer and more Apple Podcasts> Subscribe to the podcast today! The podcast is available on Spotify, Google Play, iHeartRadio, Radio Public, Amazon Music and all Android devices The Juicebox Podcast is a free show, but if you'd like to support the podcast directly, you can make a gift here or buy me a coffee. Thank you! Disclaimer - Nothing you hear on the Juicebox Podcast or read on Arden's Day is intended as medical advice. You should always consult a physician before making changes to your health plan.  If the podcast has helped you to live better with type 1 please tell someone else how to find the show and consider leaving a rating and review on Apple Podcasts. Thank you! The Juicebox Podcast is not a charitable organization.  

Speaking of SurgOnc® has a new home! New episodes can now be found under the Society of Surgical Oncology's podcast, SurgOnc Today®, available on all major podcast platforms. Subscribe today to receive updates on new episode releases.  In this new episode of Speaking of SurgOnc®, Dr. Rick Greene discusses with Dr. Mark Truty the prognosis, and response to neoadjuvant chemotherapy, of resected invasive intraductal papillary mucinous cystic neoplasms compared with de novo pancreatic ductal adenocarcinoma, as reported in their article, "Outcomes of Neoadjuvant Chemotherapy for Invasive Intraductal Papillary Mucinous Neoplasm Compared with de Novo Pancreatic Adenocarcinoma."

To have your question featured in a future video, please email: questions@drmdc.health Please include at least: Age, Weight and as much history as possible.

CME credits: 0.25 Valid until: 13-01-2026 Claim your CME credit at https://reachmd.com/programs/cme/diagnosis-and-management-of-metastatic-pdac/26434/ Pancreatic ductal adenocarcinoma, otherwise known as PDAC, is a lethal disease which is usually diagnosed at an advanced stage and has an extremely poor prognosis. Advancements in treatment regimens have improved survival rates, but early diagnosis is crucial for improving outcomes and awareness of risk factors is vital for early diagnosis. Cytotoxic chemotherapy is the cornerstone of treatment for advanced or metastatic cases, although molecularly targeted therapies and immunotherapies may benefit select patients. Treatment selection depends on several factors, including patients' performance status and co-morbidities and these should be considered alongside the efficacy and safety profiles of the different chemotherapy regimens. This 2-part microlearning provides an overview of the risk factors, diagnostic tools and treatment options available to date for different patient groups. Complete both modules, answer pre- and post-test questions and start earning CME credits. This programme is also featured on the COR2ED website, here: Metastatic pancreatic ductal adenocarcinoma (PDAC): from diagnosis to treatment

CME credits: 0.25 Valid until: 13-01-2026 Claim your CME credit at https://reachmd.com/programs/cme/chemotherapy-strategies-for-metastatic-pdac/26435/ Pancreatic ductal adenocarcinoma, otherwise known as PDAC, is a lethal disease which is usually diagnosed at an advanced stage and has an extremely poor prognosis. Advancements in treatment regimens have improved survival rates, but early diagnosis is crucial for improving outcomes and awareness of risk factors is vital for early diagnosis. Cytotoxic chemotherapy is the cornerstone of treatment for advanced or metastatic cases, although molecularly targeted therapies and immunotherapies may benefit select patients. Treatment selection depends on several factors, including patients' performance status and co-morbidities and these should be considered alongside the efficacy and safety profiles of the different chemotherapy regimens. This 2-part microlearning provides an overview of the risk factors, diagnostic tools and treatment options available to date for different patient groups. Complete both modules, answer pre- and post-test questions and start earning CME credits. This programme is also featured on the COR2ED website, here: Metastatic pancreatic ductal adenocarcinoma (PDAC): from diagnosis to treatment

In today's episode, supported by Merus, we had the pleasure of speaking with Alison Schram, MD, about the FDA approval of zenocutuzumab-zbco (Bizengri) for patients with previously treated advanced pancreatic adenocarcinoma or non–small cell lung cancer (NSCLC) harboring NRG1 gene fusions. Dr Schram is an assistant attending physician at Memorial Sloan Kettering Cancer Center in New York, New York.  On December 4, 2024, the FDA granted accelerated approval to zenocutuzumab for the treatment of adult patients with advanced, unresectable, or metastatic pancreatic adenocarcinoma harboring an NRG1 gene fusion who have disease progression on or after prior systemic therapy; and adult patients with advanced, unresectable, or metastatic NSCLC harboring an NRG1 gene fusion who have disease progression on or after prior systemic therapy. This regulatory decision was based on findings from the phase 2 eNRGy trial (NCT02912949), in which patients with pancreatic adenocarcinoma (n = 30) achieved an overall response rate (ORR) of 40% (95% CI, 23%-59%), and a duration of response (DOR) that ranged from 3.7 months to 16.6 months. In the NSCLC cohort (n = 64), the (ORR) of 33% (95% CI, 22%-46%), and the median DOR was 7.4 months (95% CI, 4.0-16.6).  In our exclusive interview, Dr Schram discussed the significance of this approval, key efficacy data from the pancreatic cancer and NSCLC cohorts of eNRGy, and the importance of using RNA-based testing to identify patients with NRG1 fusions. 

FDA D.I.S.C.O. Burst Edition: FDA approval of Bizengri (zenocutuzumab-zbco) for Treatment of adults with advanced unresectable or metastatic pancreatic adenocarcinoma harboring a neuregulin 1 (NRG1) gene fusion with disease progression on or after prior systemic therapy

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/AAPA information, and to apply for credit, please visit us at PeerView.com/ZDG865. CME/MOC/AAPA credit will be available until November 13, 2025.Renewed Optimism for Personalized Care in Advanced Pancreatic and Extra-Pancreatic Neuroendocrine Tumors: The Evolving Role and Clinical Applications of Emerging Strategies to Improve Patient Outcomes In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis educational activity is supported by medical education grants from Exelixis, Inc. and Novartis Pharmaceuticals Corporation.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/AAPA information, and to apply for credit, please visit us at PeerView.com/ZDG865. CME/MOC/AAPA credit will be available until November 13, 2025.Renewed Optimism for Personalized Care in Advanced Pancreatic and Extra-Pancreatic Neuroendocrine Tumors: The Evolving Role and Clinical Applications of Emerging Strategies to Improve Patient Outcomes In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis educational activity is supported by medical education grants from Exelixis, Inc. and Novartis Pharmaceuticals Corporation.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/AAPA information, and to apply for credit, please visit us at PeerView.com/ZDG865. CME/MOC/AAPA credit will be available until November 13, 2025.Renewed Optimism for Personalized Care in Advanced Pancreatic and Extra-Pancreatic Neuroendocrine Tumors: The Evolving Role and Clinical Applications of Emerging Strategies to Improve Patient Outcomes In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis educational activity is supported by medical education grants from Exelixis, Inc. and Novartis Pharmaceuticals Corporation.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/AAPA information, and to apply for credit, please visit us at PeerView.com/ZDG865. CME/MOC/AAPA credit will be available until November 13, 2025.Renewed Optimism for Personalized Care in Advanced Pancreatic and Extra-Pancreatic Neuroendocrine Tumors: The Evolving Role and Clinical Applications of Emerging Strategies to Improve Patient Outcomes In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis educational activity is supported by medical education grants from Exelixis, Inc. and Novartis Pharmaceuticals Corporation.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/AAPA information, and to apply for credit, please visit us at PeerView.com/ZDG865. CME/MOC/AAPA credit will be available until November 13, 2025.Renewed Optimism for Personalized Care in Advanced Pancreatic and Extra-Pancreatic Neuroendocrine Tumors: The Evolving Role and Clinical Applications of Emerging Strategies to Improve Patient Outcomes In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis educational activity is supported by medical education grants from Exelixis, Inc. and Novartis Pharmaceuticals Corporation.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/AAPA information, and to apply for credit, please visit us at PeerView.com/ZDG865. CME/MOC/AAPA credit will be available until November 13, 2025.Renewed Optimism for Personalized Care in Advanced Pancreatic and Extra-Pancreatic Neuroendocrine Tumors: The Evolving Role and Clinical Applications of Emerging Strategies to Improve Patient Outcomes In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis educational activity is supported by medical education grants from Exelixis, Inc. and Novartis Pharmaceuticals Corporation.Disclosure information is available at the beginning of the video presentation.

Sometimes all of us have pains all over our bodies and don't understand why. Did you know what kind of pain is associated with each body organ? However, note that this information is of an introductory kind and shouldn't be taken as a strict guide. TIMESTAMPS Heart 0:36 Kidneys 1:00 Small intestine 1:21 Large intestine 1:37 Lungs 1:51 Appendix 2:13 Stomach 2:37 Gallbladder and liver 3:04 Pancreas 3:26 SUMMARY If something is wrong with the heart, a person feels compressing pain in the chest that can spread to the left arm, shoulder blade, and part of the neck.  Kidney pain can sometimes be confused with a simple backache. The difference is that kidney pain is deeper under the ribs, while muscle pain is usually lower. Problems with the small intestine usually cause pain in the navel region. If the pain persists and causes discomfort when bending or walking, don't put off a visit to a doctor. Issues with the large intestine are usually associated with pain in the lower abdomen, closer to the right side.  The lungs themselves don't feel pain due to a lack of nerve endings. But if something's wrong with them, you may feel a dull ache in your chest. The appendix is located in the lower right region of the abdomen, but pain may affect the whole stomach area or its separate parts. The pain may also travel to your right thigh. Other signs of issues with the appendix are nausea, vomiting, fever, and constipation or diarrhea. Gastric problems cause pain in the middle abdominal region above the ribs and can also appear on the same level in the back. Gallbladder and liver problems may cause pain in the upper right region of the abdomen. It can also travel to the same place in the back. Liver issues are also associated with a wide range of symptoms, such as a sour taste in the mouth and jaundice. Pancreatic problems are indicated by pain in the middle part of the upper abdominal region. However, a less intense pain may also travel to the whole stomach. Don't forget to hit the like button below the video, share it with others, and click subscribe to join the Bright Side of life! Subscribe to Bright Side: https://goo.gl/rQTJZz ---------------------------------------------------------------------------------------- Our Social Media: Facebook:   / brightside   Instagram:   / brightgram   5-Minute Crafts Youtube: https://www.goo.gl/8JVmuC  ---------------------------------------------------------------------------------------- For more videos and articles visit: http://www.brightside.me/ Learn more about your ad choices. Visit megaphone.fm/adchoices

The pancreatic anastomosis is often regarded as the “Achilles Heel” of the Whipple operation, as technical failure and leakage is a significant source of perioperative morbidity and mortality. In this episode from the HPB team at Behind the Knife listen in as we discuss the standard techniques for the anastomosis, alternative techniques for the pancreatic anastomosis in patients with aberrant anatomy and/or physiology, key factors to consider when selecting the ideal approach/technique for the anastomosis, and mitigation strategies for leaks.  Hosts Anish J. Jain MD (@anishjayjain) is a current PGY3 General Surgery Resident at Stanford University and a former T32 Research Fellow at the University of Texas MD Anderson Cancer Center. Jon M. Harrison is a 2nd year HPB Surgery Fellow at Stanford University. He previously completed his general surgery residency at Massachusetts General Hospital, and will be returning to MGH as faculty at the conclusion of his fellowship.    Monica M. Dua (@MonicaDuaMD) is a Clinical Professor of Surgery and the Associate Program Director of the HPB Surgery Fellowship at Stanford University. She also serves as also serves as the regional HPB Surgeon at the VA Palo Alto Health Care System. Learning Objectives · Develop an understanding of the standard technical approaches to the pancreatic anastomosis during a Whipple (pancreatoduodenectomy) operation · Develop an understanding of the alternative technical approaches to the pancreatic anastomosis during the Whipple when the standard approaches may not be feasible · Develop an understanding of the key anatomic and physiologic factors in the decision making when selecting the optimal approach for the pancreatic anastomosis · Develop an understanding of possible mitigation strategies in the event of a pancreatic anastomotic leak. Suggested Reading Jon Harrison, Monica M. Dua, William V. Kastrinakis, Peter J. Fagenholz, Carlos Fernandez-del Castillo, Keith D. Lillemoe, George A. Poultsides, Brendan C. Visser, Motaz Qadan. “Duct tape:” Management strategies for the pancreatic anastomosis during pancreatoduodenectomy. Surgery. Volume 176, Issue 4, 2024, Pages 1308-1311, https://pubmed.ncbi.nlm.nih.gov/38796390/ Please visit https://behindtheknife.org to access other high-yield surgical education podcasts, videos and more.   If you liked this episode, check out our recent episodes here: https://app.behindtheknife.org/listen

BUFFALO, NY - November 4, 2024 – A new #casereport was #published in Oncotarget's Volume 15 on October 11, 2024, entitled “A case of adenosquamous pancreatic cancer with a KRAS G12C mutation with an exceptional response to immunotherapy.” This case report highlights a remarkable and unexpected response to immunotherapy in a patient with metastatic adenosquamous pancreatic cancer (ASCP), a rare and aggressive form of pancreatic cancer. The study, led by Murtaza Ahmed, Brent K. Larson, Arsen Osipov, Nilofer Azad, and Andrew Hendifar from Cedars-Sinai Medical Center and Johns Hopkins University, provides new hope for ASCP patients, who are traditionally underserved by current treatment options. The team documented a 68-year-old male with metastatic ASCP carrying a KRAS G12C mutation. Unexpectedly, after limited success with standard therapies, the patient's cancer responded significantly to pembrolizumab, a type of immune checkpoint inhibitor, despite the absence of typical markers indicating suitability for immunotherapy. Pancreatic cancer remains one of the most lethal cancer types, with few advancements in effective treatments for its rarer forms, such as ASCP, which accounts for only 1-10% of all pancreatic cancer cases. Traditionally, ASCP has been treated with chemotherapy based on protocols for the more common pancreatic ductal adenocarcinoma, despite the distinct tumor characteristics. This case suggests that ASCP's unique tumor microenvironment may make it more receptive to immunotherapy. Researchers are hopeful that this new understanding will drive clinical trials focused on immunotherapy specifically for ASCP patients, potentially offering new options for those with limited treatment success. “To that point, there is an active multi-center phase 2 trial investigating outcomes and responses to ICI in patients with metastatic or unresectable ASCP or ampullary cancer.” In conclusion, this report signals a potential shift in the treatment of rare and aggressive pancreatic cancer subtypes like ASCP. As oncology increasingly embraces personalized medicine, cases like this one open new avenues for patients who were not responsive to traditional therapies, potentially transforming the management of previously intractable cancers. DOI - https://doi.org/10.18632/oncotarget.28659 Correspondence to - Andrew Hendifar - andrew.hendifar@cshs.org Video short - https://www.youtube.com/watch?v=VnfohGvfMoM Sign up for free Altmetric alerts about this article - https://oncotarget.altmetric.com/details/email_updates?id=10.18632%2Foncotarget.28659 Subscribe for free publication alerts from Oncotarget - https://www.oncotarget.com/subscribe/ Keywords - cancer, pancreatic cancer, immunotherapy, metastasis About Oncotarget Oncotarget (a primarily oncology-focused, peer-reviewed, open access journal) aims to maximize research impact through insightful peer-review; eliminate borders between specialties by linking different fields of oncology, cancer research and biomedical sciences; and foster application of basic and clinical science. Oncotarget is indexed and archived by PubMed/Medline, PubMed Central, Scopus, EMBASE, META (Chan Zuckerberg Initiative) (2018-2022), and Dimensions (Digital Science). To learn more about Oncotarget, please visit https://www.oncotarget.com and connect with us: Facebook - https://www.facebook.com/Oncotarget/ X - https://twitter.com/oncotarget Instagram - https://www.instagram.com/oncotargetjrnl/ YouTube - https://www.youtube.com/@OncotargetJournal LinkedIn - https://www.linkedin.com/company/oncotarget Pinterest - https://www.pinterest.com/oncotarget/ Reddit - https://www.reddit.com/user/Oncotarget/ Spotify - https://open.spotify.com/show/0gRwT6BqYWJzxzmjPJwtVh MEDIA@IMPACTJOURNALS.COM

Ahsen Ustaoglu interviews Dr Matthias Brugel on their targeted screening analysis of pancreatic adenocarcinoma risk with organoclorine pesticides from the PESTIPAC study

Dr. Thomas Clancy joins Radio Boston to discuss pancreatic surgery using an operative robot.

Today's guest is my dear friend Brenda Holley. She is a master coach, helping professionals thrive in their careers. She and Paul have been married for eighteen years. She is mom to two adult sons. I've been friends with Brenda for several years, so I was honored when she reached out to me soon after receiving a diagnosis of pancreatic cancer.Pancreatic cancer has a bad reputation because the prognosis is often extremely grim. While she knew this fact, she chose not to entertain it or dwell on it. Instead, she decided she would fight to overcome it.Brenda's positive mental attitude going into this cancer journey would be incredibly helpful. During our interview, Brenda admitted she hadn't made God a priority over the last few years. Her diagnosis changed that. She said, “I leaned into my faith.” Praying healing verses out loud, reading God's Word, and getting quiet were and continue to be Brenda's daily practices.Brenda was eager to share the valuable wisdom she gained during her cancer journey.The book Brenda mentioned in her interview is Charles Capps' book titled God's Creative Power for Healing. It can be purchased on Amazon. Notable quotes from this episode with Brenda Holley: ·         “Unfortunately, it took a really scary experience to put me right back into the Presence of God. And I discovered so much love and support there.”·         Thank God for His faithfulness even when we're not doing a good job. Because He's always there to pick up those pieces, and there's no judgment. There's only love.”·         “I have also found it helpful to read those Scriptures out loud. If you say them, you get to see what you say.”·         “The more you dig in there and study it [Scripture], the richer it gets.”·         “One other thing that I did that I've used a lot is I made a physical list . . . of all the things that showed God's hand on my situation . . . I go back and look at it all the time.”Bible verse: ·         Jeremiah 1:12 “I am watching over My Word to perform it.”·         Hebrews 1:3 “He is upholding all things by the Word of His power.” Connect with Brenda Holley:Her website: https://brendaholley.comOn Facebook: https://www.facebook.com/brenda.holley.946On Instagram:  https://www.instagram.com/coachbrendaholleySend me a COMMENT or QUESTION!

Thank you for joining us for our 2nd Cabral HouseCall of the weekend! I'm looking forward to sharing with you some of our community's questions that have come in over the past few weeks…   Ali: Hello Dr.Cabral. Can you please explain low pancreatic elastase on stool test. I have no GI symptoms or diagnosed disease, but out of curiosity ran comprehensive stool analysis, where pancreatic enzymes were low, butyrate producing bacteria were low and a positive h.pylori was found. Can those two be related? What specific food & supplements can I take to increase pancreatic elastase when dealing with h.pylori? Also, what's your stand on clostridium butyricum as a probiotic supplement to increase butyrate production? Thank you     Patrick: Hey dr hope all is well. I know theres certain things you don't like to talk about for certain reasons but i was wondering if you could give some information on getting a tetanus shot. Im 50 and know Its been a while since i have had one. Thanks keep up the great work     Lauren: (Product Review) have you heard of the sanctuary holistic wellness detox? Is it a good option for a detox? Is it normal to see parasites? Or is that too extreme of a detox?     Josh: Good Morning, Re-listening to latest mindpump episode with Dr Stephen Cabral 2332 and he mentions 10 vitality tests but only mentions one that I can find (A full body MRI). Looking to see what the complete list of 10 vitality tests are and if there is any content where this is posted to review. Thanks in advance for any info. Regards, Josh     Anonymous: Hi Dr Cabral, I am a 63 year old female, not overweight, moderate exercise x3/week. High cholesterol runs in my family and mine's been high since my twenties. I just got my bloods back and total cholesterol is 8.3, HDL 1.5 , LDL6.4, Triglycerides normal. Lipoprotein ratio is 0.89. I have always eaten high carb, lots of sugar. My doctor has insisted on putting me on Statins since an ultrasound of my carotic arteries shows minor very soft plaque, lining within normal limits. I have now cut out sugar and added more fish, meat eggs, Omega 3, magnesium and vitamin D. Now I'm worried that the increased protein especially meat and eggs will raise my cholesterol level further. Would Berberine help for cholesterol? I often have low blood sugar so does that matter? Many thanks in advance!   Thank you for tuning into this weekend's Cabral HouseCalls and be sure to check back tomorrow for our Mindset & Motivation Monday show to get your week started off right!   - - - Show Notes and Resources: StephenCabral.com/3117 - - - Get a FREE Copy of Dr. Cabral's Book: The Rain Barrel Effect - - - Join the Community & Get Your Questions Answered: CabralSupportGroup.com - - - Dr. Cabral's Most Popular At-Home Lab Tests: > Complete Minerals & Metals Test (Test for mineral imbalances & heavy metal toxicity) - - - > Complete Candida, Metabolic & Vitamins Test (Test for 75 biomarkers including yeast & bacterial gut overgrowth, as well as vitamin levels) - - - > Complete Stress, Mood & Metabolism Test (Discover your complete thyroid, adrenal, hormone, vitamin D & insulin levels) - - - > Complete Food Sensitivity Test (Find out your hidden food sensitivities) - - - > Complete Omega-3 & Inflammation Test (Discover your levels of inflammation related to your omega-6 to omega-3 levels) - - - Get Your Question Answered On An Upcoming HouseCall: StephenCabral.com/askcabral - - - Would You Take 30 Seconds To Rate & Review The Cabral Concept? The best way to help me spread our mission of true natural health is to pass on the good word, and I read and appreciate every review!  

Sid Dogra, MD discusses a study characterizing the visibility and diameter of the pancreatic duct and common bile duct on 2D MR images in children without pancreaticobiliary disease. ARTICLE TITLE - Visibility and Size of the Pancreatic Duct and Common Bile Duct on Routine 2D MRI Sequences in Children Without Pancreaticobiliary Disease

“Our health system is $5 trillion today, and we spend 3.5% of that on preventative healthcare,” says Andrew Lacy.  Andrew, the founder and CEO of whole-body imaging company Prenuvo joins us to discuss early detection of cancer and cognitive decline and explain why preventative health care needs an update, plus: -How Prenuvo is different (~04:08) -What does Prenuvo & what does it test for? (~7:38) -What are the limitations? (~9:46) -The most common findings (~12:50) -My personal MRI experience & findings (~15:16) -Pancreatic cancer and why cancer rates are growing (~24:00) -Early biomarkers of dementia (~30:00)  -What about radiation concerns? (~33:30)  -How much does Prenuvo cost? (~34:06) -Why we need more preventative care (~35:58) -Why the current physcial exam is outdated (~37:27) -Why Andrew started Prenuvo (~40:30)  Use discount code MINDBODYGREEN at checkout or visit http://prenuvo.com/MINDBODYGREEN for $300 off your Prenuvo Whole Body scan. Go to shop.mindbodygreen.com/support15 to get 15% off your first order of methylation+. Referenced in the episode:  Prenuvo  Increasing cancer rates amongst young adults How the brain shrinks with age How much money is spent on preventative care in the U.S. We hope you enjoy this episode, and feel free to watch the full video on YouTube! Whether it's an article or podcast, we want to know what we can do to help here at mindbodygreen. Let us know at: podcast@mindbodygreen.com. Learn more about your ad choices. Visit megaphone.fm/adchoices

Eat when you can, sleep when you can, and don't F with the pancreas!  What happens when that third rule goes wrong, and why do people say pancreas injuries are like eating crawfish?  Whether you love the pancreas or just the mention of the P-word strikes fear in your heart, or if you just want the answer to the aforementioned questions, join Drs. Cobler-Lichter, Kwon, and Meizoso, as they guide you through all this and more!  Hosts: - Michael Cobler-Lichter, MD, PGY3, University of Miami/Jackson Memorial Hospital/Ryder Trauma Center, @mdcobler (twitter) - Eugenia Kwon, MD, Trauma/Surgical Critical Care Fellow, University of Miami/Jackson Memorial Hospital/Ryder Trauma Center -Jonathan Meizoso, MD, MSPH Assistant Professor of Surgery, 4 years in practice, University of Miami/Jackson Memorial Hospital/Ryder Trauma Center, @jpmeizoso (twitter) Learning Objectives: - Describe the AAST grading system for pancreatic injuries - Come up with a treatment plan for each grade of pancreatic injury - Identify commonly associated injuries with pancreatic trauma -  List potential complications of pancreatic trauma and/or surgery Quick Hits: 1. Pancreas injuries do not all require a trip to the operating room. Low grade injuries should be managed with a trial of nonoperative management if there are no other operative indications 2. CT is the best initial imaging modality, although it has low sensitivity. If there is high concern for a pancreas injury based on mechanism or associated injuries, further investigation is required. 3. Pancreas injuries are like crawfish: suck the head and eat the tail. 4. Injuries to the left of the SMV can generally be treated with distal pancreatectomy and splenectomy, whereas injuries to the right of the SMV are usually drained. 5. Its important to identify and address any concomitant injuries, with duodenal injuries being the most common in higher grade injuries. 6. In the case of the dreaded grade 5 injury, the safe answer is to come back and do your reconstruction at a later time. References 1.     https://www.westerntrauma.org/western-trauma-association-algorithms/management-of-pancreatic-injuries/ 2.     Bassi, Claudio et al. The 2016 update of the International Study Group (ISGPS) definition and grading of postoperative pancreatic fistula: 11 Years After. Surgery, Volume 161, Issue 3, 584 – 591 https://pubmed.ncbi.nlm.nih.gov/28040257/ Please visit https://behindtheknife.org to access other high-yield surgical education podcasts, videos and more.   If you liked this episode, check out our recent episodes here: https://app.behindtheknife.org/listen

Thank you for joining us for our 2nd Cabral HouseCall of the weekend! I'm looking forward to sharing with you some of our community's questions that have come in over the past few weeks…   Lisa: Hello Again Dr. Cabral, In addition to having a Mega-stomach & colon along with LIMO, which seems to reoccur, I have IPMN branch cysts on my pancreas which have not changed in the last 6 months so will be monitored annually. I am not sure if this has attributed to my conditions, but I do take a digestive enzyme along with HCL with each meal. I am not sure if I am taking enough, but I take what I can afford. My GI doctors have been stumped by my conditions, but did offer antibiotics for my LIMO, which I am considering because my insurance will cover it and I am out of money. What would you do if you had these conditions?   Anonymous: Hello! I am currently taking the pill form of birth control. I plan to come off of the birth control in about 6 months. I plan to test my hormones at that point to start rebalancing. I also would like to do the Cbo protocol due to excessive gas and bloating I've experienced for several years now. I am wondering if it would be a good idea to do the Cbo protocol while still on the birth control or should I wait until I have come off of it. I know the birth control can have negative affects on my gut so I don't want to slow my gut healing by doing it while still on the birth control. thank you.   Lindsay: Hello,I loved today's episode on rice. I eat a lot of Banza. It's a chickpea rice. what are your thoughts on that? https://www.eatbanza.com/products/chickpea-rice-garlic-olive-oil   Luis: Hi Dr. Cabral, Do you have any thoughts on Monoatomic Gold? How about Colloidal Silver as a daily mouth wash? Thanks   Jessica: Hi Dr. Cabral, I've learned so much from you. Thank you for all you do to empower so many people! My question is on melatonin. I know you've done many episodes on melatonin and are generally a proponent of its usage in moderate amounts. I typically take 2-3 mg per night. But there are a lot of people in the health space who do not think taking melatonin is a good idea. I hear them usually say something about it being a hormone and not wanting to introduce external hormones to the body if you can help it. But I've always found their rationale to be vague. I know you've done so much research on melatonin. Could you articulate the “steel man” argument for why taking 1-5mg of melatonin every night may not be a good idea?   Jessica: One more question on melatonin - Would you advise someone stop taking melatonin when they become pregnant? That seems to be the conventional wisdom because there is little research on it. But, in theory, it seems like melatonin could be useful for calming the mother's central nervous system, improving sleep, providing antioxidants, etc. — all of which would be favorable to the baby.   Thank you for tuning into this weekend's Cabral HouseCalls and be sure to check back tomorrow for our Mindset & Motivation Monday show to get your week started off right! - - - Show Notes and Resources: StephenCabral.com/2928 - - - Get a FREE Copy of Dr. Cabral's Book: The Rain Barrel Effect - - - Join the Community & Get Your Questions Answered: CabralSupportGroup.com - - - Dr. Cabral's Most Popular At-Home Lab Tests: > Complete Minerals & Metals Test (Test for mineral imbalances & heavy metal toxicity) - - - > Complete Candida, Metabolic & Vitamins Test (Test for 75 biomarkers including yeast & bacterial gut overgrowth, as well as vitamin levels) - - - > Complete Stress, Mood & Metabolism Test (Discover your complete thyroid, adrenal, hormone, vitamin D & insulin levels) - - - > Complete Food Sensitivity Test (Find out your hidden food sensitivities) - - - > Complete Omega-3 & Inflammation Test (Discover your levels of inflammation related to your omega-6 to omega-3 levels) - - - Get Your Question Answered On An Upcoming HouseCall: StephenCabral.com/askcabral - - - Would You Take 30 Seconds To Rate & Review The Cabral Concept? The best way to help me spread our mission of true natural health is to pass on the good word, and I read and appreciate every review!  

Thank you for joining us for our 2nd Cabral HouseCall of the weekend! I'm looking forward to sharing with you some of our community's questions that have come in over the past few weeks…   Jeffrey: Hello from one of your grateful students, I searched the podcast for info on a product called Transfer Factor, but found no results. I have a potential client who's recovering from chemo / Pancreatic tumor and is taking the product to support immunity. (from Web MD: A transfer factor is a chemical that is taken from a human or animal that has already developed protection (immunity) against a certain disease.) Would love to hear your thoughts on it, also compared to the Immunity Protocol. Thanks!   Zach: Yo, doc C. What's good homie!? I have two questions. First question: did moose Cabral have a middle name? Second question: what is your favorite cookie or cookies if you have more than 1? P.s- you are the man! Thank you for continuously dropping gems of knowledge for all to hear and learn. Keep up the great work! Much appreciated   Angie: My daughter is going on a missions trip to Peru in March. It is suggested that she take typhoid and malaria pills before departure. I would rather not do this. What would a natural recommendation be?   Lauren: Hello! I have lymph nodes in my neck and by my collar bone that have been noticeable for over a year now. When I've been to my primary care doctor she just said it's normal when your body is fighting an infection. But this has been forever! They don't seem to be getting bigger but they also aren't going away. I am also very puffy. I can't do anything to get the puffiness to go away. I did take your inflammation test and I was off the charts with inflammation. I also did the food sensitivity test and the only thing slightly sensitive was sesame, brazil nuts and vanilla. i've stayed away from those and nothing has changed. My doctors have also told me I have very low blood pressure. I'm not sure if any of this is related. Any suggestions? Thanks!   Marisa: Are there any dietary changes or supplements I can implement to help reduce inflammation in my child that has an auto inflammatory condition (PFAPA). Could this be related to his impulsivity/ADHD?   Katarzyna: Hej, My name's Katarzyna and i want to Lose some weight. Can you help me? Kind regards   Thank you for tuning into this weekend's Cabral HouseCalls and be sure to check back tomorrow for our Mindset & Motivation Monday show to get your week started off right!   - - - Show Notes and Resources: StephenCabral.com/2921 - - - Get a FREE Copy of Dr. Cabral's Book: The Rain Barrel Effect - - - Join the Community & Get Your Questions Answered: CabralSupportGroup.com - - - Dr. Cabral's Most Popular At-Home Lab Tests: > Complete Minerals & Metals Test (Test for mineral imbalances & heavy metal toxicity) - - - > Complete Candida, Metabolic & Vitamins Test (Test for 75 biomarkers including yeast & bacterial gut overgrowth, as well as vitamin levels) - - - > Complete Stress, Mood & Metabolism Test (Discover your complete thyroid, adrenal, hormone, vitamin D & insulin levels) - - - > Complete Food Sensitivity Test (Find out your hidden food sensitivities) - - - > Complete Omega-3 & Inflammation Test (Discover your levels of inflammation related to your omega-6 to omega-3 levels) - - - Get Your Question Answered On An Upcoming HouseCall: StephenCabral.com/askcabral - - - Would You Take 30 Seconds To Rate & Review The Cabral Concept? The best way to help me spread our mission of true natural health is to pass on the good word, and I read and appreciate every review!